Suppr超能文献

阿片类药物的差异:药理学、实验、临床和经济学角度。

Differences between opioids: pharmacological, experimental, clinical and economical perspectives.

机构信息

Mech-Sense, Department of Gastroenterology & Hepatology, Aalborg Hospital, Aarhus University Hospital, Aalborg, Denmark.

出版信息

Br J Clin Pharmacol. 2013 Jan;75(1):60-78. doi: 10.1111/j.1365-2125.2012.04317.x.

Abstract

Clinical studies comparing the response and side effects of various opioids have not been able to show robust differences between drugs. Hence, recommendations of the regulatory authorities have been driven by costs with a general tendency in many countries to restrict physician's use of opioids to morphine. Although this approach is recognized as cost-effective in most cases there is solid evidence that, on an individual patient basis, opioids are not all equal. Therefore it is important to have an armamentarium of strong analgesics in clinical practice to ensure a personalized approach in patients who do not respond to standard treatment. In this review we highlight differences between opioids in human studies from a pharmacological, experimental, clinical and health economics point of view. We provide evidence that individuals respond differently to opioids, and that general differences between classes of opioids exist. We recommend that this recognition is used to individualize treatment in difficult cases allowing physicians to have a wide range of treatment options. In the end this will reduce pain and side effects, leading to improved quality of life for the patient and reduce the exploding pain related costs.

摘要

临床研究比较了各种阿片类药物的反应和副作用,但未能显示出药物之间的明显差异。因此,监管机构的建议是基于成本的,许多国家普遍倾向于限制医生使用阿片类药物,只限于使用吗啡。尽管这种方法在大多数情况下是具有成本效益的,但有确凿的证据表明,就个体患者而言,阿片类药物并不完全相同。因此,在临床实践中拥有一套强有力的镇痛药物非常重要,以确保对标准治疗无反应的患者能够采取个性化的治疗方法。在这篇综述中,我们从药理学、实验、临床和健康经济学的角度强调了人类研究中阿片类药物之间的差异。我们提供的证据表明,个体对阿片类药物的反应不同,而且阿片类药物的类别之间存在一般差异。我们建议,在困难情况下应根据这种认识进行个体化治疗,允许医生有广泛的治疗选择。最终,这将减轻疼痛和副作用,提高患者的生活质量,并降低与疼痛相关的不断膨胀的成本。

相似文献

1
Differences between opioids: pharmacological, experimental, clinical and economical perspectives.
Br J Clin Pharmacol. 2013 Jan;75(1):60-78. doi: 10.1111/j.1365-2125.2012.04317.x.
5
Pain treatment with opioids : achieving the minimal effective and the minimal interacting dose.
Clin Drug Investig. 2009;29 Suppl 1:3-16. doi: 10.2165/0044011-200929001-00002.
6
7
Pain management in patients with cancer: focus on opioid analgesics.
Curr Pain Headache Rep. 2011 Aug;15(4):271-9. doi: 10.1007/s11916-011-0201-7.
8
Opioid and adjuvant analgesics: compared and contrasted.
Am J Hosp Palliat Care. 2011 Aug;28(5):378-83. doi: 10.1177/1049909111410298. Epub 2011 May 26.
9
Pharmacoeconomic Analysis of Pain Medications Used to Treat Adult Patients with Chronic Back Pain in the United States.
J Pain Palliat Care Pharmacother. 2016 Dec;30(4):300-307. doi: 10.1080/15360288.2016.1231735. Epub 2016 Oct 17.
10
Trends in opioid consumption in the Nordic countries 2002-2006.
Eur J Pain. 2009 Oct;13(9):954-62. doi: 10.1016/j.ejpain.2008.11.006. Epub 2008 Dec 16.

引用本文的文献

2
An Effectiveness and Tolerability of Tapentadol Nasal Spray in Low Back Pain.
J Orthop Case Rep. 2025 Jun;15(6):242-249. doi: 10.13107/jocr.2025.v15.i06.5726.
4
Persistent Transcriptome Alterations in Zebrafish Embryos After Discontinued Opioid Exposure.
Int J Mol Sci. 2025 May 19;26(10):4840. doi: 10.3390/ijms26104840.
5
Brain Cytochrome P450: Navigating Neurological Health and Metabolic Regulation.
J Xenobiot. 2025 Mar 14;15(2):44. doi: 10.3390/jox15020044.
6
Opioidergic pain relief in humans is mediated by beta and high-gamma modulation in limbic regions.
medRxiv. 2025 Mar 28:2025.03.03.25323046. doi: 10.1101/2025.03.03.25323046.
7
Pharmacokinetics of Opioid Infusions in the Adult Intensive Care Unit Setting-A Systematic Review.
Clin Pharmacokinet. 2025 Mar;64(3):323-334. doi: 10.1007/s40262-025-01490-8. Epub 2025 Mar 1.
8
Misuse, Abuse and Medication Errors' Adverse Events Associated with Opioids-A Systematic Review.
Pharmaceuticals (Basel). 2024 Jul 31;17(8):1009. doi: 10.3390/ph17081009.
10
Neuroimaging of opioid exposure: a review of preclinical animal models to inform addiction research.
Psychopharmacology (Berl). 2023 Dec;240(12):2459-2482. doi: 10.1007/s00213-023-06477-6. Epub 2023 Oct 19.

本文引用的文献

2
Use of opioid analgesics in the treatment of cancer pain: evidence-based recommendations from the EAPC.
Lancet Oncol. 2012 Feb;13(2):e58-68. doi: 10.1016/S1470-2045(12)70040-2.
3
Switching from oxycodone to methadone in advanced cancer patients.
Support Care Cancer. 2012 Jan;20(1):191-4. doi: 10.1007/s00520-011-1259-9. Epub 2011 Sep 7.
4
Current considerations for the treatment of severe chronic pain: the potential for tapentadol.
Pain Pract. 2012 Apr;12(4):290-306. doi: 10.1111/j.1533-2500.2011.00487.x. Epub 2011 Jul 29.
6
Do CYP2D6 genotypes reflect oxycodone requirements for cancer patients treated for cancer pain? A cross-sectional multicentre study.
Eur J Clin Pharmacol. 2012 Jan;68(1):55-64. doi: 10.1007/s00228-011-1093-5. Epub 2011 Jul 7.
7
Conversion ratios for opioid switching in the treatment of cancer pain: a systematic review.
Palliat Med. 2011 Jul;25(5):504-15. doi: 10.1177/0269216311406577.
10
Treatment of cancer pain.
Lancet. 2011 Jun 25;377(9784):2236-47. doi: 10.1016/S0140-6736(11)60236-5.

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验